Navigation Links
Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery
Date:10/23/2007

WASHINGTON, Oct. 23 /PRNewswire-FirstCall/ -- Two carotid stenting trials examining outcomes in real-world patients demonstrated for the first time results that are comparable to guidelines established by the American Heart Association (AHA)(1) for patients treated with carotid artery surgery. The results of these studies were presented today in a late-breaking clinical trials session at the Cardiovascular Research Foundation's 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium by William Gray, M.D., FACC, of Columbia University Medical Center in New York.

Patients treated with carotid stents in Abbott's CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events) and EXACT(TM) (Emboshield and Xact Post Approval Carotid Stent Trial) post-marketing trials, which enrolled 4,111 patients, demonstrated 30 day patient outcome results that are comparable to the AHA outcome guidelines for patients less than 80 years old who undergo carotid surgery (carotid endarterectomy). These guidelines recommend stroke and death rates that are within 3% for patients without symptoms of stroke (asymptomatic) and 6% for patients with symptoms of stroke (symptomatic).

"With these two very large, well-conducted, real-world carotid artery stenting trials, not only has carotid stenting achieved a comparable outcome to guidelines established for patients who undergo carotid surgery, but it also did so in a population of patients who are at high risk for experiencing adverse events from surgery," said Dr. Gray. "This is significant because this is the first time physicians have achieved results in high surgical risk candidates that are comparable to the long-standing guidelines that were established for lower surgical risk candidates, demonstrating that stenting can provide a reliable non-surgical alternative for patients facing the difficult decision of how to manage their carotid artery disease."

In 1998, the American Heart Association published its 30 day outcome guidelines in Circulation for patients treated with carotid artery surgery. These guidelines were based on the observed stroke and death rates in patients with carotid artery disease who had undergone surgery, or carotid endarterectomy, to treat their condition. The patients who underwent carotid artery surgery were at standard risk for experiencing an adverse event from surgery. Abbott's post-marketing CAPTURE 2 and EXACT studies are the first real-world carotid artery stenting studies to demonstrate results comparable to these goals.

About Abbott's CAPTURE 2 and EXACT Post-Marketing Clinical Studies

The CAPTURE 2 study included 1,987 patients and utilized Abbott's ACCULINK(TM) Carotid Stent System and ACCUNET(TM) Embolic Protection System. The EXACT study included 2,124 patients and utilized Abbott's Xact(R) Rapid Exchange Carotid Stent System and Emboshield BareWire(TM) Rapid Exchange Embolic Protection System. The key objective of both trials was to determine whether carotid stenting could be performed safely in real-world clinical setting by physicians with varying levels of experience. The primary endpoints were death, stroke and MI at 30 days. The demographics of patients in both trials were similar.

The 30-day composite endpoints of stroke and death for patients in the CAPTURE 2 and EXACT studies were:

-- 3.1% and 3.0% combined stroke and death in CAPTURE 2 and EXACT patients

without symptoms under age 80

-- 6.0% and 7.3% combined stroke and death in CAPTURE 2 and EXACT patients

with symptoms under age 80

-- 3.8% and 4.0% stroke and death within 30-days of treatment for the

combined patient populations

"We are very pleased with the findings from the CAPTURE 2 and EXACT trials, which show that patients treated with Abbott's ACCULINK and XACT carotid artery stent systems can have outcomes comparable to those of patients who undergo carotid surgery," said Charles D. Foltz, vice president, Abbott Vascular. "With approximately 15,000 patients enrolled across our six carotid artery stenting trials, Abbott continues to lead both the understanding and development of less invasive treatment methods for patients with carotid artery disease, which is a cause of stroke."

Patient enrollment for the CAPTURE 2 trial is ongoing. The EXACT trial is closed and 30-day follow up has been completed.

About Stroke

Approximately 25 percent of strokes are caused by carotid artery disease. In carotid artery disease, arteries located on either side of the neck that supply blood to the brain become narrowed or blocked due to the deposition of fatty plaques that can lead to stroke. Stroke is the third leading cause of death in the United States and the number one cause of disability in adults, according to the American Heart Association. More than 700,000 Americans will have new (500,000) or recurrent (200,000) strokes each year, and more than 150,000 will die from the events.

About Carotid Artery Stenting

Carotid artery stenting is a minimally invasive alternative treatment to surgery in which a stent is inserted into carotid arteries in the neck in order to stabilize fatty plaque deposits and re-establish adequate blood flow to the brain. Carotid stenting is usually accompanied by an embolic protection filter designed to capture and remove any debris that becomes dislodged during a carotid stenting procedure. Currently, carotid artery stenting in the United States is approved by the FDA for treating patients who are at high risk for experiencing adverse events from surgery or carotid endarterectomy -- an invasive procedure in which the artery is surgically opened and the plaque is removed. Abbott's carotid stenting devices are also being investigated in a broader group of patients who are not at high risk from surgery in two randomized clinical trials called CREST and ACT I, which are comparing stenting to surgery.

For images of Abbott's carotid stent and embolic protection systems and other information, please visit the company's online TCT newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

References

(1) Circulation 1998;97;501-509


'/>"/>
SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Studies On Hearing Loss Discovers New Causes
2. Broccoli Found to Block Cancer Progression In Both Animal and Human Studies
3. Studies Advocate Natural Form Of Vitamin E
4. Cure For Autism Could Be Established Through Hamster Studies
5. Despite More Studies Researchers Are Still Confound With ADHD
6. Studies Show Brain becomes Less Specialized With Age
7. ISB To Establish Research Chair On Real Estate And Urban Studies
8. Studies Show Combination Drugs As A Poor Substitute For Anti-Coagulants In Stroke
9. Further Studies Needed To Completely Understand About Ventricular Fibrillation
10. Studies Report Mammograms Unsafe
11. Six Indians Win Australian Studies Fellowships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
Breaking Medicine Technology: